AMWL, US03044L2043

American Well stock fell 3.35 percent on October 2

Published on 10/04/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

American Well stock posted a USD 12.39 last price on October 2, while Q2 revenue reached USD 52.05 million. The VA letter and USD 12.80 analyst target frame the next test.

AMWL, US03044L2043, Illustration mit AI erstellt.

American Well (ISIN US03044L2043) stock was last at USD 12.39 on the NYSE on October 2, 2026 at 4:00 p.m. ET, down 3.35 percent from USD 12.82. The latest strategic marker is a September 8 letter of intent from the Department of Veterans Affairs, while the second-quarter figures show a company still balancing revenue pressure against improving operating discipline.

Revenue reached USD 52.05 million

According to Investing.com in its Q2 2026 results summary, revenue was USD 52.05 million in the quarter ended June 30, 2026, down 26.6 percent from the prior-year quarter. The same report put adjusted loss per share at USD 0.59, which beat the consensus estimate of USD 0.89 loss by USD 0.30.

The quality of the quarter was stronger below the revenue line. Adjusted EBITDA loss narrowed to USD 1.15 million from USD 4.7 million a year earlier, while operating expenses declined 38 percent year over year, according to Investing.com.

VA opportunity carries execution risk

The Department of Veterans Affairs said on September 8, 2026 that it intends to deploy Amwell's virtual health platform across the VA enterprise. The GlobeNewswire release said the platform is expected to support clinical services and care coordination for more than nine million veterans.

The letter is strategically important because it could expand Amwell's government business, but the release also states that it is not a binding contract. A definitive agreement still depends on negotiations and federal procurement requirements, leaving conversion and timing as the central operational test.

Consensus target sits above the stock

Investing.com lists a Neutral consensus from 7 analysts, with 1 Buy, 6 Hold ratings and 0 Sell ratings. The average 12-month price target is USD 12.80, with a high estimate of USD 16.00 and a low estimate of USD 11.00.

Against the October 2 price of USD 12.39, the average target lies 3.31 percent above the stock. That narrow spread places greater weight on execution: Amwell raised 2026 revenue guidance to USD 200 million-USD 205 million and improved its adjusted EBITDA loss outlook to USD 7 million-USD 9 million, according to Investing.com.

American Well stock stays below its yearly high

American Well stock was last at USD 12.39 on the NYSE on October 2, 2026 at 4:00 p.m. ET, with a 52-week range of USD 3.71 to USD 14.19 and market capitalization of USD 210.7 million. The next valuation checkpoint is whether the VA opportunity and the profitability improvements can offset the 26.6 percent year-over-year revenue decline.